SCHEMBL3392587

SCHEMBL3392587

CCOC(=O)c1cc(F)c(F)cc1OC1CCC2CN(C(=O)OC(C)(C)C)C(C(=O)O)CC2C1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
GRIK1 P39086 5/20 0.35
GRIA2 P42262 2/20 0.35
DPP4 P27487 1/20 0.34
GPR119 Q8TDV5 2/20 0.33
NR1H2 P55055 1/20 0.33
NR1H3 Q13133 1/20 0.33
PDE4B Q07343 1/20 0.33
SCN9A Q15858 2/20 0.32
POLB P06746 2/20 0.32
TP53 P04637 1/20 0.32
HPGD P15428 2/20 0.32
ALDH1A1 P00352 2/20 0.32
KDM4E B2RXH2 1/20 0.32
RXFP1 Q9HBX9 1/20 0.32
LMNA P02545 1/20 0.32
GAA P10253 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
NPSR1 Q6W5P4 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3389093 0.90 GRIK1 (0.39) GRIK1GRIA2DPP4GPR119PDE4B
SCHEMBL3303656 0.90 GRIK1 (0.39) GRIK1GRIA2DPP4GPR119PDE4B
SCHEMBL3391628 0.88 MEN1 (0.43) MEN1KMT2AGRIK1GRIA2PDE4B
SCHEMBL3388752 0.86 GRIK1 (0.45) MEN1KMT2AGRIK1GRIA2POLB
SCHEMBL3391505 0.86 GRIK1 (0.45) MEN1KMT2AGRIK1GRIA2POLB
SCHEMBL3395047 0.85 GRIK1 (0.47) MEN1KMT2AGRIK1GRIA2HPGD
SCHEMBL3391187 0.84 MEN1 (0.39) MEN1KMT2AGRIK1GPR119TP53
SCHEMBL3297263 0.82 MEN1 (0.34) MEN1KMT2AGRIK1GRIA2DPP4
SCHEMBL3300074 0.78 GRIK1 (0.55) MEN1KMT2AGRIK1GRIA2PDE4B
SCHEMBL3391432 0.78 GRIK1 (0.55) MEN1KMT2AGRIK1GRIA2PDE4B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2166003-A1 Excitatory amino acid receptor antagonists Eli Lilly & Company (US) 2010-03-24 EP disclosed
US-20060100237-A1 Excitatory amino acid receptor antagonists ARNOLD MACKLIN B 2006-05-11 US disclosed
US-20040138254-A1 Excitatory amino acid receptor antagonists ELI LILLY AND COMPANY 2004-07-15 US disclosed
EP-1368032-A1 EXCITATORY AMINO ACID RECEPTOR ANTAGONISTS ELI LILLY AND COMPANY (US) 2003-12-10 EP disclosed
WO-2003024453-A1 EXCITATORY AMINO ACID RECEPTOR ANTAGONISTS ELI LILLY AND COMPANY (US) 2003-03-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040138254-A1 Excitatory amino acid receptor antagonists SLC1A2, SLC1A1, GRIN1 MEN1 1115/4885KMT2A 1887/4885GRIK1 8/4885
US-20060100237-A1 Excitatory amino acid receptor antagonists SLC1A2, SLC1A1, GRIN1 MEN1 1115/4885KMT2A 1887/4885GRIK1 8/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.